← Back to Search

Erythropoietin Stimulating System

ESS for Anemia

Phase 3
Waitlist Available
Research Sponsored by Targeted Medical Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

The objective of this study is to measure the change in blood values after the administration of an amino acid based erythropoietin stimulating system.

Eligible Conditions
  • Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hemoglogin/Hematocrit
Secondary outcome measures
IGF-1
Red blood cell count
Reticulocyte count

Trial Design

1Treatment groups
Experimental Treatment
Group I: ESSExperimental Treatment1 Intervention
Prescription medical food erythropoietin stimulating system

Find a Location

Who is running the clinical trial?

Targeted Medical PharmaLead Sponsor
7 Previous Clinical Trials
428 Total Patients Enrolled
1 Trials studying Anemia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby May 2025